


Dr Lal PathLabs with Ibex Medical Analytics to deliver AI-powered cancer diagnostics

24 November 2021 | News

Dr Lal PathLabs will deploy the Galen platform, supporting pathologists with multi-tissue, AI-driven insights in real-time



Dr Lal PathLabs and Ibex Medical Analytics, the market leader in artificial intelligence (AI)-powered cancer diagnostics, announced the first deployment in India of an AI platform that supports pathologists during routine cancer diagnosis and helps improve the quality and turnaround time of cancer tests.

Ibex's AI technology and Philips' IntelliSite pathology solution demonstrated impressive performance across multiple clinical studies and in live clinical deployments in Europe and the US. This partnership marks a continued journey to find the most innovative products that help patients and doctors.

Ibex transforms cancer diagnosis by harnessing artificial intelligence and machine learning technologies at an unprecedented scale. Ibex's Galen platform helps pathologists improve the quality of cancer diagnosis, implement real-time quality control, reduce diagnosis time and boost productivity. The platform was recently granted Breakthrough Device Designation by the US Food and Drug Administration (FDA) and is CE marked in Europe for breast and prostate cancer detection in multiple workflows.